Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

130 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Biogen Inc., Q1 2024 Earnings Call, Apr 24, 2024
Alzheimer's drug adoption in US slowed by doctors' skepticism
RE
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
PU
Transcript : Biogen Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 10:00 AM
Biogen : to Participate in the Stifel 2024 Virtual CNS Days
PU
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GL
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
AQ
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
GL
Transcript : Biogen Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 11:10 AM
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GL
Transcript : Biogen Inc., Q4 2023 Earnings Call, Feb 13, 2024
Biogen: approval for Friedreich's ataxia in the EU
CF
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GL
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
AQ
Biogen to Realign Resources for Alzheimer's Disease Franchise
GL
Biogen to Realign Resources for Alzheimer's Disease Franchise
AQ
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
GL
Transcript : Biogen Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 09:10 AM
Transcript : Biogen Inc., Q3 2023 Earnings Call, Nov 08, 2023
Biogen : Q3 2023 Biogen Earnings Presentation
PU
Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi
RE
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
GL
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
AQ
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GL
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
AQ
Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023
CI
Biogen Appoints Jane Grogan as Head of Research
GL
Biogen Appoints Jane Grogan as Head of Research
AQ
Transcript : Biogen Inc., Q2 2023 Earnings Call, Jul 25, 2023
Biogen : Q2 2023 Biogen Earnings Presentation
PU
Thomas Cook India : Details of share liable to be transferred to the IEPF authority - 2023
PU
Transcript : Biogen Inc., Q1 2023 Earnings Call, Apr 25, 2023
Biogen : Q1 2023 Biogen Earnings Presentation
PU
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
GL
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
AQ
Transcript : Biogen Inc. Presents at Stifel 2023 Virtual CNS Days, Mar-28-2023 09:15 AM
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
GL
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
AQ
Biogen : to Participate in the Stifel 2023 CNS Days
PU
Transcript : Biogen Inc. Presents at Cowen 43rd Annual Healthcare Conference, Mar-06-2023 09:50 AM
Transcript : Biogen Inc., Q4 2022 Earnings Call, Feb 15, 2023
Biogen : Q4 and Full Year 2022 Biogen Earnings Presentation
PU
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
GL
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
BU
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
AQ
Biogen splits R&D division ahead of key decision on Alzheimer's drug
RE
Biogen names Priya Singhal as head of development after splitting R&D division
RE
Biogen Names Priya Singhal as Executive Vice President, Head of Development
GL
Biogen Names Priya Singhal as Executive Vice President, Head of Development
AQ
Biogen Names Priya Singhal as Executive Vice President, Head of Development
CI
No results for this search
  1. Stock Market
  2. Advanced search
  3. Priya Singhal
  4. News
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW